FDA authorizes Pfizer’s COVID-19 vaccine booster for U.S. adults
November 19, 2021; 8:32 AM EST
(Reuters) – The U.S. Food and Drug Administration on Friday authorized booster doses of Pfizer Inc (PFE.N) and BioNTech SE’s COVID-19 vaccine for all adults, a move aimed at addressing waning protection among fully vaccinated Americans in the face of Delta variant-driven breakthrough cases of the illness.
A U.S. Centers for Disease Control and Prevention advisory panel is expected to meet later in the day to discuss whether to recommend the booster doses for the broader population. read more
Our Standards: The Thomson Reuters Trust Principles.